Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Boehringer pens €1.05B deal for Simcere's IBD bispecific
Boehringer has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical IBD bispecific antibody.
James Waldron
Jan 27, 2026 7:30am
Caldera launches with $112M to fund IBD drug from China
Jan 14, 2026 9:10am
AstraZeneca pens fresh IBD collab with Immunai worth $85M
Oct 16, 2025 9:00am
Genentech pens $420M deal for Omass' preclinical IBD program
Sep 2, 2025 3:00am
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Aug 13, 2025 1:48pm
Lilly inks $50M deal for biotech's FXR program
Feb 26, 2025 5:35am
